论文部分内容阅读
目的探讨莫西沙星联合萘普生治疗耐多药肺结核的临床疗效。方法选取2013年5月—2014年5月宜春市人民医院收治的耐多药肺结核患者68例,随机分为观察组与对照组,各34例。观察组患者予以莫西沙星联合萘普生治疗,对照组患者予以左氧氟沙星治疗。观察两组患者痰菌转阴情况、X线表现改善情况及不良反应发生情况。结果观察组患者治疗3、6、9个月痰菌转阴率高于对照组,X线表现改善率高于对照组,不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论莫西沙星联合萘普生治疗耐多药肺结核的临床疗效显著,可提高患者痰菌转阴率和X线表现改善率,且不良反应少。
Objective To investigate the clinical efficacy of moxifloxacin and naproxen in the treatment of multi-drug resistant pulmonary tuberculosis. Methods From May 2013 to May 2014, 68 patients with MDR-TB in Yichun People’s Hospital were randomly divided into observation group and control group, with 34 cases in each group. Patients in the observation group were treated with moxifloxacin combined with naproxen, and patients in the control group were treated with levofloxacin. The two groups of patients with sputum negative conversion, X-ray performance and adverse reactions occurred. Results In the observation group, the negative rate of sputum bacteria was higher than that of the control group at 3, 6, and 9 months after treatment, the improvement rate of X-ray was higher than that of the control group, and the incidence of adverse reactions was lower than that of the control group (P <0.05 ). Conclusion The clinical efficacy of moxifloxacin and naproxen in the treatment of multidrug-resistant pulmonary tuberculosis is significant, which can improve the rate of sputum negative conversion rate and X-ray performance in patients with less adverse reactions.